Retrospective study evaluating relationship between endoscopic healing index scores and therapeutic drug monitoring across biologics in Crohn's Disease
Latest Information Update: 22 Dec 2020
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 22 Dec 2020 New trial record
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020